Melphalan Flufenamide PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Melphalan flufenamide is a peptide-conjugated alkylating agent designed to be taken up by cells and cleaved by intracellular peptidases to release melphalan. Melphalan alkylates DNA, causing DNA crosslinking and inhibition of DNA synthesis and tumour-cell proliferation.
Indications / reported uses
Historical US indication: in combination with dexamethasone for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy and refractory to specified prior agents. US approval was withdrawn effective 23 February 2024; do not present it as a current US-authorised treatment.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Melphalan Flufenamide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Melphalan Flufenamide Permitted Daily Exposure (PDE) report (the Melphalan Flufenamide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Melphalan Flufenamide Occupational Exposure Limit (OEL) report (the Melphalan Flufenamide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.